BOND PHARMACY, INC. v. Anazaohealth Corp.

815 F. Supp. 2d 966, 2011 U.S. Dist. LEXIS 117876, 2011 WL 4766444
CourtDistrict Court, S.D. Mississippi
DecidedFebruary 11, 2011
Docket1:11-cv-00058
StatusPublished
Cited by4 cases

This text of 815 F. Supp. 2d 966 (BOND PHARMACY, INC. v. Anazaohealth Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
BOND PHARMACY, INC. v. Anazaohealth Corp., 815 F. Supp. 2d 966, 2011 U.S. Dist. LEXIS 117876, 2011 WL 4766444 (S.D. Miss. 2011).

Opinion

ORDER DENYING PRELIMINARY INJUNCTION

CARLTON W. REEVES, District Judge.

The above-styled cause is before the Court on the Plaintiff’s motion for a preliminary injunction. After having considered the parties’ pleadings, briefs, exhibits, testimony, and arguments, the Court finds that the motion should be and hereby is denied.

FACTS

Pursuant to Rule 52(a) of the Federal Rules of Civil Procedure, the Court makes the following findings of fact.

Advanced Infusion Solutions (hereinafter “AIS”) and AnazaoHealth Corporation (hereinafter “Anazao”) are competitors in the marketplace of compounded pharmaceuticals. AIS operates by creating customized mixtures of pain medication and selling them to patients, who ingest the formulas by use of surgically implanted, programmable pump devices (Durable Medical Equipment). Frequently, AIS serves customers who are insured by Medicare.

AIS and Anazao have different business models. When a physician orders a compound from Anazao, the company bills the doctor for its costs, after which the doctor awaits reimbursement from Medicare as he has represented to Medicare that the drugs are furnished “incident to” a physician service. See Exhibit A to Defendant’s Response in Opposition [8-1] (Affidavit of Jacob Beckel).

Chuck Bell, the president and CEO of AIS, testified at the hearing on his company’s motion that he believes AIS is not obligated to this process. When his company receives an order, AIS ships the compound to the patient’s physician, and the doctor (or a member of her staff) injects the medicine into the patient’s surgically implanted device. AIS then directly bills the insurance carrier, which relieves the physician from the obligations of paying for the product and waiting for reimbursement.

Anazao believes that this practice violates billing guidelines promulgated by the Centers for Medicare and Medicaid Services (hereinafter “CMS”). Anazao argues that CMS does not permit pharmacies to bill Medicare (or any private insurance carrier) directly for pain medication provided to physicians for administration to patients incident to the physicians’ office procedures. According to Anazao, “CMS Medicare billing guidelines require that the physician ‘bundle’ the cost of the medication in with the office visit charge and the pump calibration, fill and administration charges, and that only the physician and not the pharmacy could bill for practitioner administered medications.” Defendant’s Memorandum in Opposition [Docket No. 9] at 7 (emphasis included). AIS disputes this view of CMS guidelines. The dispute regarding these interpretations and the ensuing actions taken by the parties culminated in the filing of this action.

On January 18, 2011, Jacob Beckel, Anazao’s chairman and CEO, distributed a letter concerning his company’s position to current and former physician clients. Some of these physicians also use, or at least once used, AIS. The letter does not explicitly speak of AIS but refers to “a billing practice by at least one compound *970 ing pharmacy wherein the pharmacy bills Medicare directly on behalf of the physician, patient, or both.” Exhibit F to Plaintiffs Reply Brief [Docket No. 12-6]. The letter avers that Anazao consulted with legal counsel, a Medicare billing expert, and various state Medicare offices regarding the legality of this billing model and was advised that the method runs afoul of CMS guidelines. See hearing Exhibit P-3.

According to Bell, although the January 18 letter does not mention AIS by name, his company began to suffer financial injury shortly thereafter. 1 Bell complains that the letter led a group of physicians to withdraw an invitation to an important conference and that he has received repeated phone calls from doctors expressing concerns regarding the letter’s claims. Naturally, many of these physicians, according to Bell, have expressed great reluctance to do business with him or AIS for fear of being accused of Medicare fraud.

On January 31, 2011, AIS filed a Motion for Temporary Restraining Order, Preliminary Injunction and Other Relief [Docket No. 1], which it superseded on February 1, 2011, with a First Amended Motion for Temporary Restraining Order, Preliminary Injunction and Complaint for Other Relief [Docket No. 5] (herein after “the Complaint”). The prayer for relief seeks the following intervention:

AIS moves this Court for an Order against Defendant Anazao enjoining and restraining it, its officers, agents, attorneys, and all other persons acting in concert with it, or any of them for the benefit of themselves, from:
1. directly or indirectly, in his or her own capacity or through any other person or persons, contact any other person about the billing practices of AIS;
2. directly or indirectly, in his or her own capacity or through any other person (I) solicit or contact for business purposes any existing customer, supplier, or prospective customer or supplier, of AIS or any subsidiary for the purpose of improperly competing with AIS or (ii) interfere with existing or proposed agreements or other arrangements, or knowingly interfere with future agreements or other arrangements, between AIS or any subsidiary on the one hand or any other person on the other hand.

Id. at 4.

Pursuant to Rule 65 of the Federal Rules of Civil Procedure, the motion for a preliminary injunction came before the Court for a hearing at 10 am. on February 10, 2011, at which both parties were represented by counsel. 2 Counsel for AIS pre *971 sented testimony from three witnesses, and the hearing adjourned just before 5 p.m.

ANALYSIS

The ultimate success or failure of AIS’s case is not the issue before the Court. Instead, the matter at bar is AIS’s motion for a preliminary injunction, a form of relief viewed as “an extraordinary and drastic remedy....” Black Fire Fighters Ass’n of Dallas v. City of Dallas, Texas, 905 F.2d 63, 65 (5th Cir.1990). Such an order should not issue unless a denial of the motion would render the judicial process irrelevant.

A court should grant a preliminary injunction only if the movant demonstrates the following:

(1) a substantial likelihood that he will prevail on the merits, (2) a substantial threat that he will suffer irreparable injury if the injunction is not granted, (3) his threatened injury outweighs the threatened harm to the party whom he seeks to enjoin, and (4) granting the preliminary injunction will not disserve the public interest.

Bluefield Water Ass’n Inc. v. City of Starkville, Miss., 577 F.3d 250, 252-53 (5th Cir.2009).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gilmer v. Tucker
S.D. Mississippi, 2025
Moates v. Facebook Inc.
E.D. Texas, 2021
Jones v. Browning
S.D. Mississippi, 2020

Cite This Page — Counsel Stack

Bluebook (online)
815 F. Supp. 2d 966, 2011 U.S. Dist. LEXIS 117876, 2011 WL 4766444, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bond-pharmacy-inc-v-anazaohealth-corp-mssd-2011.